Treatment of dyspnoea in advanced cancer patients: ESMO Clinical Practice Guidelines

Annals of Oncology

Volumn 26, Issue , 2015, Pages v169-v173

  Kloke, M ^a   Cherny, N ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; HYDROMORPHONE; LORAZEPAM; MIDAZOLAM; MORPHINE; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; OXYGEN; STEROID;

ADVANCED CANCER; ANXIETY; ARTICLE; DYING; DYSPNEA; HUMAN; HYPOXEMIA; LUNG CANCER; OXYGEN THERAPY; PALLIATIVE THERAPY; PATIENT EDUCATION; PRIORITY JOURNAL; RELAXATION TRAINING; COMPLICATION; LUNG NEOPLASMS; PATHOLOGY;

DYSPNEA; HUMANS; LUNG NEOPLASMS;

EID: 84941645194     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv306     Document Type: Article

References (92)

1. Altfelder N, Nauck F, Alt-Epping B et al. Characteristics of patients with breathlessness-a German national survey on palliative care in-patient units. Palliat Med 2010; 24: S37 (abstract).
2. Bausewein C, Booth S, Gysels M et al. Individual breathlessness trajectories do not match summary trajectories in advanced cancer and chronic obstructive pulmonary disease: results from a longitudinal study. Palliat Med 2010; 24: 777-786.
3. Goeckenjan G, Sitter H, Thomas M et al. [Prevention, diagnosis, therapy, and follow-up of lung cancer]. Pneumologie 2010; 64(Suppl 2): e1-e164 [Article in German].
4. Gysels MH, Higginson IJ. Caring for a person in advanced illness and suffering from breathlessness at home: threats and resources. Palliat Support Care 2009; 7: 153-162.
5. Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1, 000 patients. Support Care Cancer 2000; 8: 175-179.
6. American Thoracic Society. Dyspnea-mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med 1999; 159: 321-340.
7. Henoch I, Bergman B, Danielson E. Dyspnea experience and management strategies in patients with lung cancer. Psychooncology 2008; 17: 709-715.
8. Parshall MB, Schwartzstein RM, Adams L et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012; 185: 435-452.
9. Abernethy AP, Wheeler JL. Total dyspnoea. Curr Opin Support Palliat Care 2008; 2: 110-113.
10. von Leupoldt A, Balewski S, Petersen S et al. Verbal descriptors of dyspnea in patients with COPD at different intensity levels of dyspnea. Chest 2007; 132: 141-147.
11. Tishelman C, Degner LF, Rudman A et al. Symptoms in patients with lung carcinoma: distinguishing distress from intensity. Cancer 2005; 104: 2013-2021.
12. Bausewein C, Jolley C, Reilly C. Development, effectiveness and cost-effectiveness of a new out-patient Breathlessness Support Service: study protocol of a phase III fast-track randomised controlled trial. BMC Pulm Med 2012; 12: 58.
13. Booth S, Moffat C, Farquhar M et al. Developing a breathlessness intervention service for patients with palliative and supportive care needs, irrespective of diagnosis. J Palliat Care 2011; 27: 28-36.
14. Farquhar MC, Prevost AT, McCrone P et al. Study protocol: phase III single-blinded fast-track pragmatic randomised controlled trial of a complex intervention for breathlessness in advanced disease. Trials 2011; 12: 130.
15. Bausewein C, Farquhar M, Booth S et al. Measurement of breathlessness in advanced disease: a systematic review. Respir Med 2007; 101: 399-410.
16. Bausewein C, Booth S., Higginson IJ. Measurement of dyspnoea in the clinical rather than the research setting. Curr Opin Support Palliat Care 2008; 2: 95-99.
17. Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure breathlessness in palliative care? A systematic review. Palliat Med 2007; 21: 177-191.
18. Grimbert D, Lubin O, de Monte M et al. [Dyspnea and morphine aerosols in the palliative care of lung cancer]. Rev Mal Respir 2004; 21: 1091-1097 [Article in French].
19. Simon ST, Higginson IJ, Benalia H et al. Episodic and continuous breathlessness: a new categorization of breathlessness. J Pain Symptom Manage 2013; 45: 1019-1029.
20. Reddy SK, Parsons HA, Elsayem A et al. Characteristics and correlates of dyspnea in patients with advanced cancer. J Palliat Med 2009; 12: 29-36.
21. Bailey PH. The dyspnea-anxiety-dyspnea cycle-COPD patients' stories of breathlessness: "It's scary/when you can't breathe". Qual Health Res 2004; 14: 760-778.
22. Davis CL. ABC of palliative care. Breathlessness, cough, and other respiratory problems. BMJ 1997; 315: 931-934.
23. Zabora J, BrintzenhofeSzoc K, Curbow B et al. The prevalence of psychological distress by cancer site. Psychooncology 2001; 10: 19-28.
24. Sakurada T, Kakiuchi S, Tajima S et al. Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer. Ann Pharmacother 2015; 49: 398-404.
25. Ost DE, Ernst A, Grosu HB et al. Therapeutic bronchoscopy for malignant central airway obstruction: success rates and impact on dyspnea and quality of life. Chest 2015; 147: 1282-1298.
26. Bausewein C, Booth S, Gysels M, Higginson I. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev 2008: CD005623.
27. Simon ST, Müller-Busch C, Bausewein C. [Symptom management of pain and breathlessness]. Internist (Berl) 2011; 52: 28, 30-35 [Article in German].
28. Bausewein C, Booth S, Gysels M et al. Effectiveness of a hand-held fan for breathlessness: a randomised phase II trial. BMC Palliat Care 2010; 9: 22.
29. Galbraith S, Fagan P, Perkins P et al. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J Pain Symptom Manage 2010; 39: 831-838.
30. Probst VS, Troosters T, Coosemans I et al. Mechanisms of improvement in exercise capacity using a rollator in patients with COPD. Chest 2004; 126: 1102-1107.
31. Booth S, Silvester S, Todd C. Breathlessness in cancer and chronic obstructive pulmonary disease: using a qualitative approach to describe the experience of patients and carers. Palliat Support Care 2003; 1: 337-344.
32. Booth S, Moosavi SH, Higginson IJ. The etiology and management of intractable breathlessness in patients with advanced cancer: a systematic review of pharmacological therapy. Nat Clin Pract Oncol 2008; 5: 90-100.
33. Abernethy AP, McDonald CF, Frith PA et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet 2010; 376: 784-793.
34. Cranston JM, Crockett A, Currow D. Oxygen therapy for dyspnoea in adults. Cochrane Database Syst Rev 2008: CD004769.
35. Magnussen H, Kirsten AM, Köhler D et al. [Guidelines for long-term oxygen therapy. German Society for Pneumology and Respiratory Medicine]. Pneumologie 2008; 62: 748-756 [Article in German].
36. Uronis H, McCrory DC, Samsa G et al. Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; 15: CD006429.
37. Vogelmeier C, Buhl R, Criée CP et al. [Guidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft fur Pneumologie und Beatmungsmedizin]. Pneumologie 2007; 61: e1-e40 [Article in German].
38. Clemens KE, Klaschik E. Symptomatic therapy of dyspnea with strong opioids and its effect on ventilation in palliative care patients. J Pain Symptom Manage 2007; 33: 473-481.
39. Currow DC, McDonald C, Oaten S et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage 2011; 42: 388-399.
40. Johnson MJ, Hui D, Currow DC. Opioids, exertion, and dyspnea: a review of the evidence. Am J Hosp Palliat Care 2014 [Epub ahead of print].
41. Oxberry SG, Torgerson DJ, Bland JM. Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. Eur J Heart Fail 2011; 13: 1006-1012.
42. Caraceni A, Hanks G, Kaasa S et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13: e58-e68.
43. Johnson MJ, Abernethy AP, Currow DC. Gaps in the evidence base of opioids for refractory breathlessness. A future work plan? J Pain Symptom Manage 2012; 43: 614-624.
44. Pattinson KT, Governo RJ, MacIntosh BJ et al. Opioids depress cortical centers responsible for the volitional control of respiration. J Neurosci 2009; 29: 8177-8186.
45. Perna GP, Modoni S, Valle G et al. Plasma beta-endorphin response to exercise in patients with congestive heart failure. Chest 1997; 111: 19-22.
46. Simon ST, Köskeroglu P, Gaertner J, Voltz R. Fentanyl for the relief of refractory breathlessness-a systematic review. J Pain Symptom Manage 2013; 46: 874-886.
47. von Leupoldt A, Sommer T, Kegat S et al. The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala. Am J Respir Crit Care Med 2008; 177: 1026-1032.
48. von Leupoldt A, Sommer T, Kegat S et al. Dyspnea and pain share emotion-related brain network. Neuroimage 2009; 48: 200-206.
49. von Leupoldt A, Sommer T, Kegat S et al. Down-regulation of insular cortex responses to dyspnea and pain in asthma. Am J Respir Crit Care Med 2009; 180: 232-238.
50. Clemens KE, Klaschik E. Effect of hydromorphone on ventilation in palliative care patients with dyspnea. Support Care Cancer 2008; 16: 93-99.
51. Pang GS, Qu LM, Tan YY, Yee AC. Intravenous fentanyl for dyspnea at the end of life: lessons for future research in dyspnea. Am J Hosp Palliat Care 2014; [Epub ahead of print].
52. Woodcock AA, Gross ER, Gellert A et al. Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med 1981; 305: 1611-1616.
53. King S, Forbes K, Hanks GW et al. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med 2011; 25: 525-552.
54. Murtagh FE, Chai MO, Donohoe P et al. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother 2007; 21: 5-16.
55. Twycross R, Wilcock A. Palliative Care Formulary, 4th edition. Nottingham: Palliativedrugs.com Ltd, 2011.
56. Abernethy AP, Currow DC, Frith P et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003; 327: 523-528.
57. Bruera E, Sala R, Spruyt O et al. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage 2005; 29: 613-618.
58. Charles MA, Reymond L, Israel F. Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage 2008; 36: 29-38.
59. Clemens KE, Quednau I, Klaschik E. Is there a higher risk of respiratory depression in opioid-naive palliative care patients during symptomatic therapy of dyspnea with strong opioids? J Palliat Med 2008; 11: 204-216.
60. Allard P, Lamontagne C, Bernard P, Tremblay C. How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial. J Pain Symptom Manage 1999; 17: 256-265.
61. Navigante AH, Cerchietti LC, Castro MA et al. Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. J Pain Symptom Manage 2006; 31: 38-47.
62. Navigante AH, Castro MA, Cerchietti LC. Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. J Pain Symptom Manage 2010; 39: 820-830.
63. Simon ST, Higginson IJ, Booth S et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev 2010: CD007354.
64. Smoller JW, Pollack MH, Otto MW et al. Panic anxiety, dyspnea, and respiratory disease. Theoretical and clinical considerations. Am J Respir Crit Care Med 1996; 154: 6-17.
65. Stege G, Heijdra YF, van den Elshout FJ et al. Temazepam 10 mg does not affect breathing and gas exchange in patients with severe normocapnic COPD. Respir Med 2010; 104: 518-524.
66. O'Neill PA, Morton PB, Stark RD. Chlorpromazine-a specific effect on breathlessness? Br J Clin Pharmacol 1985; 19: 793-797.
67. Rice KL, Kronenberg RS, Hedemark LL, Niewoehner DE. Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Br J Dis Chest 1987; 81: 287-292.
68. Stark RD, Gambles SA, Lewis JA. Methods to assess breathlessness in healthy subjects: a critical evaluation and application to analyse the acute effects of diazepam and promethazine on breathlessness induced by exercise or by exposure to raised levels of carbon dioxide. Clin Sci 1981; 61: 429-439.
69. Argyropoulou P, Patakas D, Koukou A et al. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration 1993; 60: 216-220.
70. Bushunow PW, Roscoe JA, Dudgeon DJ et al. Buspirone treatment of dyspnea in outpatients receiving chemotherapy. A University of Rochester Cancer Center Community Clinical Oncology Program (URCC CCOP) study. J Clin Oncol 29: 2011 (suppl; abstr 9023).
71. Borson S, McDonald GJ, Gayle T et al. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics 1992; 33: 190-201.
72. Eiser N, Harte R, Spiros K et al. Effect of treating depression on quality-of-life and exercise tolerance in severe COPD. COPD 2005; 2: 233-241.
73. Fritzsche A, Clamor A, von Leupoldt A. Effects of medical and psychological treatment of depression in patients with COPD-a review. Respir Med 2011; 105: 1422-1433.
74. Lacasse Y, Beaudoin L, Rousseau L, Maltais F. Randomized trial of paroxetine in end-stage COPD. Monaldi Arch Chest Dis 2004; 61: 140-147.
75. Marciniuk DD, Goodridge D, Hernandez P et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J 2011; 18: 69-78.
76. Singh NP, Despars JA, Stansbury DW et al. Effects of buspirone on anxiety levels and exercise tolerance in patients with chronic airflow obstruction and mild anxiety. Chest 1993; 103: 800-804.
77. Ström K, Boman G, Pehrsson K et al. Effect of protriptyline, 10 mg daily, on chronic hypoxaemia in chronic obstructive pulmonary disease. Eur Respir J 1995; 8: 425-429.
78. von Leupoldt A, Taube K, Lehmann K et al. The impact of anxiety and depression on outcomes of pulmonary rehabilitation in patients with COPD. Chest 2011; 140: 730-736.
79. du Bois RM, Greenhalgh PM, Southcott AM et al. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J 1999; 13: 1345-1350.
80. Vestbo J, Pauwels R, Anderson JA et al. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 2005; 60: 301-304.
81. Walters JA, Gibson PG, Wood-Baker R et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009: CD001288.
82. Yang IA, Fong KM, Sim EH et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; CD002991.
83. Zhang H, Liu C, Ji Z et al. Prednisone adding to usual care treatment for refractory decompensated congestive heart failure. Int Heart J 2008; 49: 587-595.
84. Aaron SD, Vandemheen KL, Hebert P et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003; 348: 2618-2625.
85. Milman N, Graudal N, Grode G, Munch E. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med 1994; 236: 285-290.
86. Tashkin DP, Rennard SI, Martin P et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008; 68: 1975-2000.
87. Heyse-Moore LH, Ross V, Mullee MA. How much of a problem is dyspnoea in advanced cancer? Palliat Med 1991; 5: 20-26.
88. Hu WY, Chiu TY, Cheng SY, Chen CY. Morphine for dyspnea control in terminal cancer patients: is it appropriate in Taiwan? J Pain Symptom Manage 2004; 28: 356-363.
89. Jennings AL, Davies AN, Higgins JP, Broadley K. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev 2001: CD002066.
90. Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest 1986; 89: 234-236.
91. Skaug K, Eide GE, Gulsvik A. Prevalence and predictors of symptoms in the terminal stage of lung cancer: a community study. Chest 2007; 131: 389-394.
92. Conill C, Verger E, Henríquez I et al. Symptom prevalence in the last week of life. J Pain Symptom Manage 1997; 14: 328-331.